Oncobiologics (NASDAQ:OTLK) Posts Earnings Results, Misses Estimates By $0.01 EPS

Oncobiologics (NASDAQ:OTLK) released its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01), FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.97 million.

Oncobiologics Trading Down 14.9%

NASDAQ OTLK traded down $0.13 during midday trading on Friday, hitting $0.76. The company had a trading volume of 104,469,209 shares, compared to its average volume of 17,814,098. The firm has a 50-day moving average price of $1.31 and a 200-day moving average price of $0.70. The company has a market capitalization of $112.39 million, a PE ratio of -0.65 and a beta of 0.82. Oncobiologics has a twelve month low of $0.16 and a twelve month high of $3.39.

Key Oncobiologics News

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Insider Buying and Selling at Oncobiologics

In related news, Director Faisal Ghiath Sukhtian purchased 95,398 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average price of $1.05 per share, with a total value of $100,167.90. Following the completion of the purchase, the director directly owned 220,972 shares in the company, valued at $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ghiath M. Sukhtian acquired 2,525,252 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $0.99 per share, with a total value of $2,499,999.48. Following the transaction, the director directly owned 24,617,320 shares of the company’s stock, valued at $24,371,146.80. This trade represents a 11.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 11,189,359 shares of company stock worth $7,662,666. 1.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oncobiologics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after acquiring an additional 21,941 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings raised Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. BTIG Research restated a “buy” rating and issued a $4.00 price target on shares of Oncobiologics in a research note on Friday. HC Wainwright raised their price target on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Ascendiant Capital Markets boosted their price objective on shares of Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oncobiologics has a consensus rating of “Hold” and an average price target of $4.65.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.